Abstract：
OBJECTIVE: Precancer biomarkers help in early detection and management of oral potentially malignant disorders (OPMDs). Interleukin-1β (IL-1β), a biomarker, is known to be altered in oral submucous fibrosis (OSMF) and oral leukoplakia (OL). Therefore, we evaluated and compared the serum and salivary IL-1β levels in patients with OSMF/oral leukoplakia and in gender- and age-matched healthy individuals.
METHODS: An in vivo, prospective, observational study was conducted on 40 subjects. Subjects were divided into two groups with 20 individuals in each group, that is, Group I: OSMF/oral leukoplakia and Group II: control group. Salivary and serum IL-1β levels were quantitatively estimated using enzyme-linked immunosorbent assay (ELISA). The statistical tests used were unpaired t-test and Chi-square test.
RESULTS: The serum IL-1β levels were significantly (P 0.001) lesser in Group I in comparison to Group II. The salivary IL-1β levels remained insignificant between both the groups. However, in both the groups, the salivary IL-1β levels were significantly higher compared to the serum IL-1β levels.
CONCLUSIONS: We found that the serum IL-1β level can be considered as a prospective biomarker for dysplasia, whereas salivary IL-1β alone needs more elaborated studies to account for its application as a potential biomarker in OPMD.
METHODS: An in vivo, prospective, observational study was conducted on 40 subjects. Subjects were divided into two groups with 20 individuals in each group, that is, Group I: OSMF/oral leukoplakia and Group II: control group. Salivary and serum IL-1β levels were quantitatively estimated using enzyme-linked immunosorbent assay (ELISA). The statistical tests used were unpaired t-test and Chi-square test.
RESULTS: The serum IL-1β levels were significantly (P 0.001) lesser in Group I in comparison to Group II. The salivary IL-1β levels remained insignificant between both the groups. However, in both the groups, the salivary IL-1β levels were significantly higher compared to the serum IL-1β levels.
CONCLUSIONS: We found that the serum IL-1β level can be considered as a prospective biomarker for dysplasia, whereas salivary IL-1β alone needs more elaborated studies to account for its application as a potential biomarker in OPMD.
摘要：
目的：癌前标志物有助于口腔潜在恶性疾病（OPMD）的早期发现和治疗。白细胞介素-1β(IL-1β),生物标志物，已知在口腔粘膜下纤维化（OSMF）和口腔白斑（OL）中发生改变。因此,我们评估并比较了OSMF/口腔白斑患者以及性别和年龄匹配的健康个体的血清和唾液IL-1β水平.
方法：体内，prospective,对40名受试者进行了观察性研究。受试者分为两组，每组20人，也就是说,I组：OSMF/口腔白斑，II组：对照组。使用酶联免疫吸附测定（ELISA）定量评估唾液和血清IL-1β水平。统计检验采用非配对t检验和卡方检验。
结果：与II组相比，I组的血清IL-1β水平显着降低（P<0.001）。两组之间的唾液IL-1β水平仍然不明显。然而,在这两个组中，唾液IL-1β水平明显高于血清IL-1β水平。
结论：我们发现血清IL-1β水平可以被认为是发育异常的前瞻性生物标志物。而单独的唾液IL-1β需要更详细的研究来解释其作为OPMD潜在生物标志物的应用。
方法：体内，prospective,对40名受试者进行了观察性研究。受试者分为两组，每组20人，也就是说,I组：OSMF/口腔白斑，II组：对照组。使用酶联免疫吸附测定（ELISA）定量评估唾液和血清IL-1β水平。统计检验采用非配对t检验和卡方检验。
结果：与II组相比，I组的血清IL-1β水平显着降低（P<0.001）。两组之间的唾液IL-1β水平仍然不明显。然而,在这两个组中，唾液IL-1β水平明显高于血清IL-1β水平。
结论：我们发现血清IL-1β水平可以被认为是发育异常的前瞻性生物标志物。而单独的唾液IL-1β需要更详细的研究来解释其作为OPMD潜在生物标志物的应用。
